The aim of the study was to determine the expression of WW domain containing oxidoreductase (WWOX) in patients with prostate cancer (PCa) and to evaluate the correlation of WWOX expression and patients survival.
Immunohistochemistry (IHC) was applied to detect the WWOX expression. Chi-square test was adopted to evaluate the relationship between WWOX expression and clinical features of PCa patients. In addition, Kaplan-Meier curve was made to estimate the survival rate of PCa patients. Multivariate analysis was performed to assess the statistical significance between WWOX expression and prognosis of PCa patients.
WWOX was weakly expressed in PCa tissues compared to the paired normal tissues by IHC. WWOX expression was tightly associated with Gleason score, PSA and clinical staging (P < 0.05), but has no relationship with age, tumor column, distant metastasis and ALP (P > 0.05). Survival curve demonstrated that patients with negative WWOX expression had lower survival rate. Finally, Cox analysis illustrated that WWOX was related with the prognosis of PCa patients (P = 0.001, HR = 4.605, 95% CI = 1.814–11.690).
In short, the present study showed strong evidence that WWOX could act as an indicator for prognosis of PCa patients.